Minerva Neurosciences Details Confirmatory Phase 3 Trial for Roluperidone in Schizophrenia
Summary
Minerva Neurosciences disclosed the design and timeline for its confirmatory Phase 3 trial of roluperidone for negative symptoms in schizophrenia, with initiation expected in Q2 2026 and topline results in H2 2027.
Key Events
-
Phase 3 Trial Details Disclosed
The company provided additional details for its proposed confirmatory Phase 3 trial of roluperidone for negative symptoms in schizophrenia during a virtual KOL event.
-
Trial Initiation and Design
The trial is expected to initiate in Q2 2026, enrolling 380 patients randomized 1:1 to receive either placebo or a 64 mg dose of roluperidone. The primary endpoint is the change in PANSS Marder negative symptoms factor score at 12 weeks.
-
Key Milestones Announced
Topline efficacy results are anticipated in the second half of 2027, with relapse assessment data expected in the second half of 2028.
Analysis
Minerva Neurosciences has provided crucial details regarding the design and timeline for its proposed confirmatory Phase 3 trial of roluperidone. This clarity on the clinical path for their lead candidate, targeting negative symptoms in schizophrenia, is a significant development for investors. The trial's initiation in Q2 2026 and expected topline results in H2 2027 provide a concrete roadmap for a key value driver. While subject to FDA feedback, the detailed plan reduces uncertainty and outlines the company's strategy for advancing roluperidone.
At the time of this filing, NERV was trading at $4.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $202.5M. The 52-week trading range was $1.15 to $12.46. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.